Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes.

Saved in:
Bibliographic Details
Title: Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes.
Authors: Liu X; Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China.; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China., Liu Y; Clinical Pharmacology Research Center, Peking Union Medical College Hospital and Chinese Academy of Medical Sciences, Beijing, China.; Department of Pharmacology, College of Pharmacy, Inner Mongolia Medical University, Hohhot, China., Liu H; Clinical Pharmacology Research Center, Peking Union Medical College Hospital and Chinese Academy of Medical Sciences, Beijing, China., Li H; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.; Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China., Yang J; Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China., Hu P; Clinical Pharmacology Research Center, Peking Union Medical College Hospital and Chinese Academy of Medical Sciences, Beijing, China., Xiao X; Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital and Chinese Academy of Medical Sciences, Beijing, China., Liu D; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.; Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Source: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2021 Sep 20; Vol. 12, pp. 694390. Date of Electronic Publication: 2021 Sep 20 (Print Publication: 2021).
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1664-2392
DOI:10.3389/fendo.2021.694390